We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA has issued California-based drugmaker SuperGen a warning letter for using a misleading mechanism of action booth panel and handout to promote its leukemia drug Nipent.
Wyeth has launched a unique support program for patients taking the firm’s antidepressant Effexor XR. The program aims to improve patient and physician communications.
Pfizer has pledged not to run direct-to-consumer (DTC) advertisements for new drugs until it has had at least six months to educate physicians about the products — move that builds on the DTC advertising code released recently by PhRMA.
There currently is no institution or organization capable of disseminating the amount of information that consumers receive from direct-to-consumer (DTC) advertising, said a drug industry observer who argues against any move to ban or over-regulate the DTC practice.
Building upon the direct-to-consumer (DTC) advertising code released last week by PhRMA, Pfizer has pledged not to run advertisements for new medicines until it has had at least six months to educate physicians about the products.
The pharmaceutical industry’s direct-to-consumer (DTC) advertising practices are responsible for escalating drug prices, Senate Majority Leader Bill Frist (R-Tenn.) said in a recent speech.
Two powerful Republican senators have expressed skepticism about the drug industry’s ability to self-regulate its direct-to-consumer (DTC) advertising practices under PhRMA’s new code of conduct.
Pharmaceutical companies must target their direct-to-consumer (DTC) advertisements at age-appropriate audiences, and firms no longer will be able to run reminder ads that don’t clearly state the disease condition the product treats, according to PhRMA’s new guiding principles on DTC drug promotions.